Argenx Se (ARGX) Non-Current Deffered Revenue (2016 - 2020)
Argenx Se's (ARGX) quarterly Non-Current Deffered Revenue came in at -$269.0 million in Q4 2021, down 202.92% YoY from $261.4 million in Q4 2020, and little changed on a QoQ basis from -$269.0 million in Q2 2021.
Analysis
Argenx Se (ARGX) Non-Current Deffered Revenue (2016 - 2020) Analysis & Trends
Argenx Se (ARGX) has 6 years of Non-Current Deffered Revenue data on file, last reported at -$269.0 million in Q4 2021.
- Quarterly Non-Current Deffered Revenue fell 202.92% year-over-year to -$269.0 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was -$269.0 million (down 202.92% YoY) and the FY2021 annual result came in at -$269.0 million, down 200.0% from the prior year.
- Non-Current Deffered Revenue held at -$269.0 million in Q4 2021, from -$269.0 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $267.1 million in Q2 2019 to a low of -$269.0 million in Q2 2021.
- A 5-year average of $26.8 million and a median of $25855.9 in 2018 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2019 — Non-Current Deffered Revenue jumped 14834.5% — and 2021, when it tumbled 1477.94%.
- Tracing ARGX's Non-Current Deffered Revenue over 5 years: stood at $1.7 million in 2017, then tumbled by 196.94% to -$1.6 million in 2018, then jumped by 14834.5% to $241.3 million in 2019, then climbed by 8.32% to $261.4 million in 2020, then slumped by 202.92% to -$269.0 million in 2021.
- The last three Non-Current Deffered Revenue figures came in at -$269.0 million (Q4 2021), -$269.0 million (Q2 2021), and $261.4 million (Q4 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 261.41 Bn |
| Jun 30, 2020 | 223.11 Mn |
| Dec 31, 2019 | 241.34 Mn |
| Jun 30, 2019 | 267.05 Mn |
| Dec 31, 2017 | 1.69 Mn |
| Dec 31, 2016 | 10.87 Mn |